A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Start Date
12/30/2016
Completion Date
2/1/2029
Summary
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
Detailed Description
Hematuria is the most common presentation of BCa with 8% of patients with microscopic hematuria harboring BCa. VUC is the most widely used urine-based assay for detecting BCa; however, it fails to detect approximately 50% of low-grade or early stage BCa when it is most curable. Because of this severe limitation, patients with hematuria will undergo an invasive examination of the urinary bladder, where a miniature camera is inserted into the bladder. We propose to improve the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
Eligibility Criteria
Age Range: 18 years to 90 years
Conditions
Locations
VA Long Beach Healthcare System
Long Beach, California 90822
United States
Cedars-Sinai Medical Center
Los Angeles, California 90048
United States
UCLA Medical Center
Los Angeles, California 90095
United States
Hoag Memorial Hospital Presbyterian
Newport Beach, California 92663
United States
University of Rochester Medical Center
Rochester, New York 14620
United States
UT Southwestern Medical Center at Dallas
Dallas, Texas 75390
United States
Nara Prefecture Seiwa Medical Center
Nara, Nara 636-0802
Japan
Nara Medical University
Nara,
Japan